The AIDS Malignancy Consortium (AMC) was established in 1995 to evaluate clinical interventions for the treatment and prevention of malignancies in HIV and to investigate the biology of malignancies in the context of clinical trials. The Group Chair's office has the overall responsibility for the entire AMC, a streamlined Executive Committee has decision making authority and administrative duties;the Steering Committee is responsibility for integration of the group's scientific agenda and ongoing discussion with the scientific and site leadership of the group's scientific. Based on recommendations from the AMC members, the NCI and an outside advisory group of senior researchers and experienced clinical trialist, the AMC voted to have a more centralized leadership with a more empowered Group Chair.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA121947-05S1
Application #
8426567
Study Section
Special Emphasis Panel (ZCA1-SRLB-D (O2))
Program Officer
Liddell Huppi, Rebecca
Project Start
2006-08-29
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$450,000
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Schneider, Johann W; Dittmer, Dirk P (2017) Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol 18:529-539
Raghavendran, Anantharam; Hernandez, Alexandra L; Lensing, Shelly et al. (2017) Genital Human Papillomavirus Infection in Indian HIV-Seropositive Men Who Have Sex With Men. Sex Transm Dis 44:173-180
Chinula, Lameck; Moses, Agnes; Gopal, Satish (2017) HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities. Curr Opin HIV AIDS 12:89-95
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Palefsky, Joel M (2017) Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era. Curr Opin HIV AIDS 12:26-30
Westmoreland, Katherine D; Stanley, Christopher C; Montgomery, Nathan D et al. (2017) Hodgkin lymphoma, HIV, and Epstein-Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study. Pediatr Blood Cancer 64:
Oliver, Nora T; Chiao, Elizabeth Y (2017) Malignancies in women with HIV infection. Curr Opin HIV AIDS 12:69-76
Gopal, Satish; Fedoriw, Yuri; Kaimila, Bongani et al. (2016) CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi. PLoS One 11:e0150445
Bender Ignacio, Rachel A; Lee, Jeannette Y; Rudek, Michelle A et al. (2016) Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr 72:52-7
Chuang, Eleanore; Lim, Eunjung; Milne, Cris et al. (2016) Human Papillomavirus at Multiple Sites Associated with Anal Squamous Intraepithelial Lesions in HIV-Seropositive Individuals. Ann Clin Cytol Pathol 2:

Showing the most recent 10 out of 118 publications